APA (7th ed.) Citation

Coward, J., Lemech, C., Meniawy, T., Dupont, C. D., Gonzalez, A. M., Lim, M., . . . Shebanova, O. (2018). 1168PPhase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy288.041

Chicago Style (17th ed.) Citation

Coward, J., et al. "1168PPhase I/II Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients with Advanced/refractory Solid Tumors, with Expansion into 2L Cervical Cancer and Solid Tumors." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy288.041.

MLA (9th ed.) Citation

Coward, J., et al. "1168PPhase I/II Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients with Advanced/refractory Solid Tumors, with Expansion into 2L Cervical Cancer and Solid Tumors." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy288.041.